Updated Findings from Prostate Cancer Chemoprevention Trial
The four-year REDUCE (Reduction by DUtasteride of prostate Cancer Events) study showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8% compared to placebo. Newly released results from a follow-up study show that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported.
However, the former dutasteride group produced double the number of cancers than the former placebo group. John Schieszer has the story in today's Medical Minute.